Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease

Recruiting

Who can join

Ages 18 and older · All sexes

Full eligibility criteria

Inclusion Criteria:

* Patients with tissue confirmed solid malignancy and standard of care brain MRI with equivocal results for LMD (questionable or possible) and negative LP CSF sampling or patients with high risk clinical LMD and negative brain MR and LP CSF sampling. Initially, we will target solid tumors, but if more patients are needed to meet the study power we will enroll liquid tumors.
* Participants \> 18 years of age.
* Participants are able to consent.

Exclusion Criteria:

* Participants with CSF sampling positive for LMD or MR brain/spine with definitive evidence of LMD.
* Participants with implantable devices that can not be scanned with MR safe mode for participant safety.
* Pregnant participants or potentially pregnant participants are at risk of contrast on the fetus

Pediatric participants \< 18 years of age.

About the study

To learn if gadopiclenol (a contrast agent) used during MRI scanning can help in the detection of early LMD.

What is being tested

MRI Scan (procedure)
VUEWAY (drug)
Gadavist (drug)

Sponsor: M.D. Anderson Cancer Center · Participants: 40 · Started: Jun 10, 2026

Contact the study team

Rami Eldaya, MD · Phone: (713) 745-2945

Official record on ClinicalTrials.gov — NCT07415018

Locations in the U.S.

Texas

MD Anderson Cancer Center, Houston

Conditions

Meningeal Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.